Gritstone Oncology
Developing next-generation personalized cancer therapeutics.
Launch date
Employees
Market cap
CAD77.3m
Enterprise valuation
CAD141m (Public information from Sep 2024)
Share price
$0.63 GRTS
Emeryville California (HQ)
Financials
Estimates*
| USD | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Revenues | 4.0m | 46.7m | 9.3m | 1.3m | 7.8m | 13.2m | 12.0m |
| % growth | (8 %) | 1057 % | (80 %) | (86 %) | 487 % | 68 % | (9 %) |
| EBITDA | (99.4m) | (68.9m) | (118m) | (127m) | (130m) | (154m) | (159m) |
| % EBITDA margin | (2462 %) | (147 %) | (1278 %) | (9531 %) | (1660 %) | (1170 %) | (1323 %) |
| Profit | (105m) | (75.1m) | (120m) | (138m) | (126m) | (129m) | (200m) |
| % profit margin | (2609 %) | (161 %) | (1291 %) | (10405 %) | (1610 %) | (981 %) | (1665 %) |
| EV / revenue | -0.1x | 14.4x | 29.4x | 177.5x | 5.4x | -3.7x | -21.1x |
| EV / EBITDA | - | -9.8x | -2.3x | -1.9x | -0.3x | 0.3x | 1.6x |
| R&D budget | 88.6m | 97.5m | 111m | 127m | - | - | - |
| R&D % of revenue | 2196 % | 209 % | 1202 % | 9555 % | - | - | - |
Source: Dealroom estimates
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | N/A | - | |
$102m | Series A | ||
* | $92.7m | Series B | |
$21.0m | Series C | ||
| N/A | N/A | IPO | |
* | $125m | Post IPO Equity | |
| N/A | $20.6m | Post IPO Equity | |
* | $45.0m | Private Placement VC | |
* | N/A | $32.5m | Post IPO Equity |
| Total Funding | CAD356m | ||
Related Content
Recent News about Gritstone Oncology
EditTech stack
Tech stackLearn more about the technologies and tools that this company uses.